Corvus Pharmaceuticals NASDAQ: CRVS
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies
Name | Corvus Pharmaceuticals |
Ticker | CRVS |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Biopharmaceuticals |
Price | 4.06 |
52W Low/High | 1.74 / 5.98 |
Market cap | 114 M |
1Y Total Return |
-28.77%
Weak |
1Y Volatility |
110.47%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies
Details
Ticker | CRVS |
Name | Corvus Pharmaceuticals |
ISIN | US2210151005 |
CUSIP | |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Biopharmaceuticals |
Country | USA |
Currency | U.S. Dollar |
In Index(ices) | NASDAQ Biotechnology Index |
Share as of 1/15/21
Close Price | 4.06 |
52W Low/High | 1.74 / 5.98 |
Market cap | 114 M |
1Y Total Return |
-28.77%
Weak |
1Y Volatility |
110.47%
High Risk |
Beta | 2.88 |
PE (trailing) | - |
12M Dividends | - |
Last Dividend Date | - |
Dividend Yield | - |
Fin. Strength
Net Profit Margin | - |
Cash from Op. / Cur. Liabilities | -2.92 |
Diluted Earnings / Share | -1.51 |
ROE | - |
ROIC | -93.7% |
Price / Revenue | - |
Price / Book | 2.8 |
Price / CF | -3.4 |
Current Ratio | 4.4 |
Cur.Liabilities / Tot.Liabilities | 0.9 |
Financial Leverage | 0.06 |
in Mils USD |
rolling-year up to September
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
0
|
0
|
0
|
0
|
0
|
-
|
|
Gross Profit |
-
|
-
|
-
|
-
|
-
|
-
|
|
R&D |
34
|
37
|
40
|
46
|
25
|
-
|
|
EBITDA |
-44
|
-45
|
-47
|
-54
|
-31
|
-
|
|
Operating Income |
-45
|
-49
|
-50
|
-56
|
-32
|
-
|
|
Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
per Share | |||||||
Diluted avg Shares |
30
|
29
|
29
|
21
|
20
|
-
|
|
EPS exc. Extra |
-1.51
|
-1.57
|
-1.97
|
-2.67
|
-17.21
|
-
|
|
Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
56
|
92
|
127
|
105
|
150
|
-
|
|
Cash, Eq & Invt ShortTerm |
51
|
86
|
123
|
100
|
145
|
-
|
|
Total Current Assets |
53
|
88
|
125
|
101
|
146
|
-
|
|
Total Non-Current Assets |
3
|
5
|
3
|
4
|
4
|
-
|
|
Intangibles |
0
|
0
|
0
|
0
|
0
|
-
|
|
Total Liabilities |
14
|
12
|
8
|
11
|
7
|
-
|
|
Total Current Liabilities |
12
|
10
|
8
|
10
|
6
|
-
|
|
Long Term Debt |
2
|
3
|
1
|
1
|
1
|
-
|
|
Shareholder equity |
42
|
80
|
119
|
94
|
143
|
-
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
-35
|
-37
|
-44
|
-45
|
-22
|
-
|
|
Depreciation |
1
|
1
|
1
|
1
|
0
|
-
|
|
Cash from Investing |
49
|
5
|
-26
|
83
|
-122
|
-
|
|
Capex |
0
|
0
|
0
|
1
|
2
|
-
|
|
Cash from Financing |
0
|
0
|
66
|
0
|
71
|
-
|
|
Stock Issued |
0
|
0
|
66
|
0
|
71
|
-
|
|
Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
-
|
|
Free Cash Flow |
8
|
-39
|
-76
|
33
|
-
|
-
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
Current Ratio |
4.4
|
9.2
|
16.1
|
10.1
|
26.1
|
-
|
|
Financial Leverage D/E |
0.06
|
0.04
|
0.00
|
0.00
|
0.00
|
-
|
|
Return on Capital Avg |
-93.7%
|
-60.5%
|
-74.7%
|
-57.9%
|
-45.2%
|
-
|
|
Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available